Skip to main content
. 2016 Jul 16;7(33):53230–53244. doi: 10.18632/oncotarget.10637

Figure 1. Identification of differentially expressed genes in trastuzumab-resistant (TzR) vs trastuzumab-sensitive (TzS) tumors by RNA-seq.

Figure 1

(A) A schematic outlining overall study design. Differentially expressed genes identified in TzS vs TzR human HER2+ tumors in vivo were intersected with differentially expressed genes identified in TzS vs TzR BT474 cell lines, which led to a small list of mRNAs and lincRNAs that are associated with TzR. (B) Heatmap representation of the differentially expressed mRNAs in TzS patients (responders) vs TzR patients (non-responders). (C) Pathway analysis of differentially expressed mRNAs in tumors in vivo. Pathway names are listed on the Y-axis, the percentage of genes affected in each pathway is indicated on the X-axis, and a p-value is given at the end of each bar.